RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS’ 29.04.2022)

NEWS RELEASE

RECORDATI: PUBLIC DISCLOSURE (DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2022)

Milan, 1st April 2022 - Please be informed that the 2021 Annual Financial Report (including the Separate Financial Statements and the Consolidated Financial Statements as at 31st December 2021 with the related Directors' Management Report and the required Statements) and the 2021 Consolidated Non-Financial Statement, both accompanied by the Reports issued by the Auditing Firm, as well as the Report issued by the Board of Statutory Auditors, are available to the public, as of today, at the Company's registered office and published on the Company's website(www.recordati.it - Investors - Shareholders' Meeting section) and on the '1INFO' storage mechanism(www.1info.it).

Please further be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 17th March 2022:

• (i) the 2021 Corporate Governance Report and Ownership Structure;

• (ii) the Report on the 2022 Remuneration Policy and the remuneration paid for 2021; and

• (iii) following the issue of the Directors' Report relating to item no. 2 (Appointment of the Board of Directors) on 18th March 2022, all the remaining Directors' Reports on the items of the agenda of the Ordinary Shareholders' Meeting called for 29th April 2022,

are also available to the public, as of today, at the Company's registered office and published on the

Company's website(www.recordati.it,the first report in the Corporate Governance - Report on Corporate Governance and the Ownership Structure section; the second report in the Corporate Governance - Remuneration section; and the latest reports in the Investors - Shareholders' Meeting section) and on the '1INFO' storage mechanism(www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.

For further information:

Recordati website:www.recordati.it

Investor Relations	Investor Relations	Media Relations
Federica De Medici	Lucia Abbatantuoni	Brunswick: Barbara Scalchi / Andrea Mormandi
(39) 02 48787146	(39) 02 48787213	(39) 02 9288 6200

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1	Share Capital € 26.140.644,50 fully paid-up
20148 Milano, Italy	Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Ph. (39) 02 487871	Tax Code/VAT No. 00748210150
Fax [phone]	Milano R.E.A. No. 401832
www.recordati.com

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l

2